# Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/INSM/insmed-to-present-at-the-2026-goldman-sachs-annual-global-healthcare-conference
Ticker: INSM
Company: Insmed
Source: Insmed
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.insmed.com
## Summary

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious...

## Article Body
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

, / PRNewswire / -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET.

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . This webcast will be archived for a period of 30 days following the conclusion of this live event.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn , Instagram , YouTube , and X .

Contact:

Investors: Bryan Dunn Vice President, Investor Relations (646) 812-4030 investor.relations@insmed.com

Media: Claire Mulhearn Vice President, Corporate Communications (862) 842-6819 media@insmed.com

SOURCE Insmed Incorporated
## Recent Company News
- 2026-07-16 11:00 EST — [Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension](https://biopharmsignal.com/news/INSM/insmed-announces-positive-12-month-data-from-the-ongoing-open-label-extension-st-7880862e) — Source: Insmed
- 2026-06-25 13:46 EST — [Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory](https://biopharmsignal.com/news/INSM/insmed-appoints-samuele-butera-as-senior-vice-president-general-manager-global-respiratory) — Source: Insmed
- 2026-06-25 13:46 EST — [Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Insmed
- 2026-06-25 13:46 EST — [Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference](https://biopharmsignal.com/news/INSM/insmed-to-present-at-the-2026-goldman-sachs-annual-global-healthcare-conference) — Source: Insmed
- 2026-06-25 13:46 EST — [Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/INSM/insmed-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Insmed
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)